目的：评价更昔洛韦联合中药治疗单纯疱疹病毒性角膜炎的安全性和有效性。

方法：分别在中国期刊全文数据库、维普数据库和万方数据库等中文数据库和PubMed、Cochrane Library、EMbase等外文数据库上检索所有更昔洛韦联合中药治疗单纯疱疹病毒性角膜炎的随机对照试验，以临床治疗总有效率、复发率、治愈时间和不良反应发生率作为结局指标评价药物的有效性和安全性。采用改良Jadad评分量表评价纳入研究的质量； 使用RevMan5.3和Stata 12.0软件进行Meta分析。

结果：共纳入15篇文献，包括1 285例单纯疱疹病毒性角膜炎患者。Meta分析结果：更昔洛韦联合中药治疗组在总有效率\〖患者例数：RR=1.23，95% CI(1.15～1.31)； 患者眼数：RR=1.18，95% CI(1.02～1.38)\〗、复发率\〖RR=0.25，95% CI(0.17～0.36)\〗和治愈时间\〖MD=-7.58，95% CI(-10.89～-4.26)\〗方面优于更昔洛韦组，差异有统计学意义(P<0.05)。联合治疗组不良反应发生率与对照组比较，差异无统计学意义\〖RR=0.53，95% CI(0.23～1.22)\〗。两组患者的不良反应均较轻微，且能够自行缓解。

结论：更昔洛韦联合中药治疗单纯疱疹病毒性角膜炎能够提高疗效，减少复发，缩短疗程，且安全性好。

METHODS: All randomized controlled trials(RCTs)of ganciclovir combined with TCM for HSK were searched in CNKI, VIP, Wanfang, PubMed, Cochrane Library and EMbase database. The clinical endpoints of the total effective rate, relapse rate, heal time, and adverse reaction rate were collected to assess the drugs' efficacy and safety. The improved Jadad Scale was used to evaluate the methodological quality of included literatures. The RevMan5.3 software and Stata 12.0 were applied for meta-analysis.

RESULTS: We finally included 15 RCTs involving 1 285 patients. As for the total effective rate, relapse rate and heal time, significant differences were noted between ganciclovir combined with TCM group and ganciclovir alone group. For the total effective rate, RR and 95%CI were 1.23(1.15～1.31)according to the number of patients and 1.18(1.02-1.38)according to the number of diseased eyes. For relapse rate, RR and 95%CI were 0.25(0.17-0.36). For heal time, MD and 95%CI were -7.58(-10.89 to -4.26). No statistic difference of adverse reaction rate between the two groups was observed \〖RR=0.53, 95%CI(0.23-1.22)\〗. The side effects in the two groups were mild and could be relieved by themselves.

CONCLUSION: The ganciclovir combined with TCM can improve the total efficacy, reduce the relapse rate, and shorten the course of treatment for HSK with good safety.